Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catalent Inc.

www.catalent.com

Latest From Catalent Inc.

AbbVie And Allergan: Five Big Review Questions To Worry About

Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.

Drug Review M & A

Manufacturing Round-Up: FDA Demands Meeting With Aurobindo Over Issues At Multiple Sites

An FDA warning letter issued to Aurobindo highlights recurring failures over several sites, while Teva is setting up a biologics development campus in the US and Nexus is investing in sterile injectables capacity.

Manufacturing Compliance

Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire

Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.

Deals Business Strategies

Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development

Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
    • OTC, Consumer
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Cardinal Health PTS
  • Catalent Inc.
  • Catalent Pharma Solutions Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Catalent Inc.
  • Senior Management
  • John Chiminski, Chmn. & CEO
    Wetteny Joseph, SVP, CFO
    Scott Gunther, SVP, Quality & Reg. Affairs
    Alessandro Maselli, Pres. & COO
  • Contact Info
  • Catalent Inc.
    Phone: (732) 537-6200
    14 Schoolhouse Rd.
    Somerset, NJ 08873
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register